Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Victoria Ku

Nurse Practitioner, Acute Care Los Angeles, CA Nurse Practitioner

NPI 1790036994 CMS profile 10712210

1520 San Pablo St Ste 1000, Los Angeles, CA 90033

Open in the dashboard

General payments

$7,028

146 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Victoria Ku of Los Angeles, CA is reported in the CMS Open Payments database as having received $7,028 across 146 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,379 18
2024 General $2,634 56
2023 General $1,384 43
2022 General $1,225 19
2021 General $406 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Victoria Ku
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Victoria Ku were reported at $1,379. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Victoria Ku Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $406 $123 $38–$327 $132
2022 $1,225 $130 $44–$369 $149
2023 $1,384 $144 $49–$410 $160
2024 $2,634 $146 $48–$433 $164
2025 $1,379 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Actelion Pharmaceuticals US, Inc. $2,377 69 payments
  2. United Therapeutics Corporation $2,045 40 payments
  3. Merck Sharp & Dohme Corporation $695 13 payments
  4. Astellas Pharma US Inc $417 4 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $304 6 payments
  6. Neurocrine Biosciences, Inc. $174 1 payment
  7. AbbVie, Inc. $156 2 payments
  8. Boston Scientific Corporation $125 1 payment
  9. LifeNet Health $125 1 payment
  10. Abbott Laboratories $122 1 payment
  11. Other $488 8 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,527 138 payments
  2. Education $501 8 payments
Products named General payments · program years 2021–2025
  1. UPTRAVI $2,246 63 payments
  2. OPSUMIT $2,165 65 payments
  3. WINREVAIR $671 12 payments
  4. REMODULIN Pulmonary Arterial Hypertension $588 8 payments
  5. TYVASO Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease $522 8 payments
  6. REMODULIN Pah $368 12 payments
  7. Adempas $292 5 payments
  8. TYVASO Pah $258 7 payments
  9. Cresemba $248 2 payments
  10. ORENITRAM $243 10 payments
  11. Other $1,337 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

258

Median for Nurse Practitioner: 389

Drug cost

$12,947

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Potassium Chloride Generic 34 $6,299
Sildenafil Citrate Generic 17 $4,166
Bumetanide Generic 17 $657
Tadalafil Generic 15 $505
Spironolactone Generic 59 $398
Digoxin Generic 25 $379
Furosemide Generic 61 $255
Metolazone Generic 12 $207
Famotidine Generic 18 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$12,597

Medicare's payments for the services billed

Medicare patients

75

Average age 67

Services billed

133

48 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Chronic kidney disease 61%
Diabetes 55%
Ischemic heart disease 55%
COPD 49%
Arthritis 48%
Atrial fibrillation 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $443
$443 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $406
$406 — —
WINREVAIR
  • Merck Sharp & Dohme Corporation $369
$369 — —
TYVASO
  • United Therapeutics Corporation $369
$369 — —
REMODULIN
  • United Therapeutics Corporation $281
$281 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record